370 related articles for article (PubMed ID: 24236104)
1. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.
Bhattacharyya S; Saha S; Giri K; Lanza IR; Nair KS; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Basal E; Weaver AL; Visscher DW; Cliby W; Sood AK; Bhattacharya R; Mukherjee P
PLoS One; 2013; 8(11):e79167. PubMed ID: 24236104
[TBL] [Abstract][Full Text] [Related]
2. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer.
Chakraborty PK; Xiong X; Mustafi SB; Saha S; Dhanasekaran D; Mandal NA; McMeekin S; Bhattacharya R; Mukherjee P
Oncotarget; 2015 Nov; 6(35):37367-84. PubMed ID: 26452259
[TBL] [Abstract][Full Text] [Related]
3. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein.
Kawahara B; Ramadoss S; Chaudhuri G; Janzen C; Sen S; Mascharak PK
J Inorg Biochem; 2019 Feb; 191():29-39. PubMed ID: 30458366
[TBL] [Abstract][Full Text] [Related]
4. Effect of S-adenosyl-L-methionine (SAM), an allosteric activator of cystathionine-β-synthase (CBS) on colorectal cancer cell proliferation and bioenergetics in vitro.
Módis K; Coletta C; Asimakopoulou A; Szczesny B; Chao C; Papapetropoulos A; Hellmich MR; Szabo C
Nitric Oxide; 2014 Sep; 41():146-56. PubMed ID: 24667534
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. Cystathionine β-synthase regulates mitochondrial morphogenesis in ovarian cancer.
Chakraborty PK; Murphy B; Mustafi SB; Dey A; Xiong X; Rao G; Naz S; Zhang M; Yang D; Dhanasekaran DN; Bhattacharya R; Mukherjee P
FASEB J; 2018 Aug; 32(8):4145-4157. PubMed ID: 29494264
[TBL] [Abstract][Full Text] [Related]
7. Role of the cystathionine β-synthase/H2S system in liver cancer cells and the inhibitory effect of quinolone-indolone conjugate QIC2 on the system.
Jia H; Ye J; You J; Shi X; Kang W; Wang T
Oncol Rep; 2017 May; 37(5):3001-3009. PubMed ID: 28440458
[TBL] [Abstract][Full Text] [Related]
8. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer.
Szabo C; Coletta C; Chao C; Módis K; Szczesny B; Papapetropoulos A; Hellmich MR
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12474-9. PubMed ID: 23836652
[TBL] [Abstract][Full Text] [Related]
10. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
[TBL] [Abstract][Full Text] [Related]
11. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
13. Overproduction of H
Panagaki T; Randi EB; Augsburger F; Szabo C
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):18769-18771. PubMed ID: 31481613
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.
Zhang X; Liao X; Wang M; Liu J; Han J; An D; Zheng T; Wang X; Cheng H; Liu P
Cancer Sci; 2024 Apr; 115(4):1170-1183. PubMed ID: 38287874
[TBL] [Abstract][Full Text] [Related]
16. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
17. Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.
Santos I; Ramos C; Mendes C; Sequeira CO; Tomé CS; Fernandes DGH; Mota P; Pires RF; Urso D; Hipólito A; Antunes AMM; Vicente JB; Pereira SA; Bonifácio VDB; Nunes SC; Serpa J
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31635026
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of cystathionine β-synthetase/hydrogen sulfide inhibition in cancer.
Hellmich MR; Coletta C; Chao C; Szabo C
Antioxid Redox Signal; 2015 Feb; 22(5):424-48. PubMed ID: 24730679
[TBL] [Abstract][Full Text] [Related]
19. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.
Druzhyna N; Szczesny B; Olah G; Módis K; Asimakopoulou A; Pavlidou A; Szoleczky P; Gerö D; Yanagi K; Törö G; López-García I; Myrianthopoulos V; Mikros E; Zatarain JR; Chao C; Papapetropoulos A; Hellmich MR; Szabo C
Pharmacol Res; 2016 Nov; 113(Pt A):18-37. PubMed ID: 27521834
[TBL] [Abstract][Full Text] [Related]
20. ATP11B mediates platinum resistance in ovarian cancer.
Moreno-Smith M; Halder JB; Meltzer PS; Gonda TA; Mangala LS; Rupaimoole R; Lu C; Nagaraja AS; Gharpure KM; Kang Y; Rodriguez-Aguayo C; Vivas-Mejia PE; Zand B; Schmandt R; Wang H; Langley RR; Jennings NB; Ivan C; Coffin JE; Armaiz GN; Bottsford-Miller J; Kim SB; Halleck MS; Hendrix MJ; Bornman W; Bar-Eli M; Lee JS; Siddik ZH; Lopez-Berestein G; Sood AK
J Clin Invest; 2013 May; 123(5):2119-30. PubMed ID: 23585472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
